Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.

JAMA - 26 Feb 2014

Downing Nicholas S, Ross Joseph S

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Consumer Product Safety
Share to Genetic Predisposition to Disease
Share to Genetic Testing
Share to Government Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polymorphism, Single Nucleotide

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 24474248
DOI: 10.1001/jama.2014.148

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service.PMID 24474248Read ↗

Science and regulation. Regulating direct-to-consumer personal genome testing.Semantic proximity Read ↗

23andMe and the FDA.Semantic proximity Read ↗

23andMe, the Food and Drug Administration, and the future of genetic testing.Semantic proximity Read ↗

23andMe resumes giving consumers genetic health information: Company's tests for rare and common diseases aren't diagnostic.Semantic proximity Read ↗

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic TestingSemantic proximity Read ↗

The personal genome--the future of personalised medicine?Semantic proximity Read ↗

The way ahead for medicine with the genomic code.Semantic proximity Read ↗

[The genome and the consumer].Semantic proximity Read ↗

Patient Choice and Preventive Genomic Sequencing--More Trouble Upstream.Semantic proximity Read ↗

First CRISPR clinical trial gets green light from US panelSemantic proximity Read ↗

Non-clinical safety assessment of novel drug modalities: Genome safety perspectives on viral-, nuclease- and nucleotide-based gene therapiesSemantic proximity Read ↗

Direct‐to‐consumer genetic testing: Perspectives on its value in healthcareSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.